Gasimli, K.; Raab, M.; Tahmasbi Rad, M.; Kurunci-Csacsko, E.; Becker, S.; Strebhardt, K.; Sanhaji, M.
Sequential Targeting of PLK1 and PARP1 Reverses the Resistance to PARP Inhibitors and Enhances Platin-Based Chemotherapy in BRCA-Deficient High-Grade Serous Ovarian Cancer with KRAS Amplification. Int. J. Mol. Sci. 2022, 23, 10892.
https://doi.org/10.3390/ijms231810892
AMA Style
Gasimli K, Raab M, Tahmasbi Rad M, Kurunci-Csacsko E, Becker S, Strebhardt K, Sanhaji M.
Sequential Targeting of PLK1 and PARP1 Reverses the Resistance to PARP Inhibitors and Enhances Platin-Based Chemotherapy in BRCA-Deficient High-Grade Serous Ovarian Cancer with KRAS Amplification. International Journal of Molecular Sciences. 2022; 23(18):10892.
https://doi.org/10.3390/ijms231810892
Chicago/Turabian Style
Gasimli, Khayal, Monika Raab, Morva Tahmasbi Rad, Elisabeth Kurunci-Csacsko, Sven Becker, Klaus Strebhardt, and Mourad Sanhaji.
2022. "Sequential Targeting of PLK1 and PARP1 Reverses the Resistance to PARP Inhibitors and Enhances Platin-Based Chemotherapy in BRCA-Deficient High-Grade Serous Ovarian Cancer with KRAS Amplification" International Journal of Molecular Sciences 23, no. 18: 10892.
https://doi.org/10.3390/ijms231810892
APA Style
Gasimli, K., Raab, M., Tahmasbi Rad, M., Kurunci-Csacsko, E., Becker, S., Strebhardt, K., & Sanhaji, M.
(2022). Sequential Targeting of PLK1 and PARP1 Reverses the Resistance to PARP Inhibitors and Enhances Platin-Based Chemotherapy in BRCA-Deficient High-Grade Serous Ovarian Cancer with KRAS Amplification. International Journal of Molecular Sciences, 23(18), 10892.
https://doi.org/10.3390/ijms231810892
